Cargando…
Advanced therapies for the management of adults with pulmonary arterial hypertension due to congenital heart disease: a systematic review
Pulmonary arterial hypertension (PAH) secondary to congenital heart disease (CHD) is the third most common cause of PAH, and it is becoming increasingly common as improvements in the management of CHD have led to increased life expectancy for these patients. The medical management of PAH due to CHD...
Autores principales: | Varela, Daniel L, Teleb, Mohamed, El-Mallah, Wael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5761307/ https://www.ncbi.nlm.nih.gov/pubmed/29344382 http://dx.doi.org/10.1136/openhrt-2017-000744 |
Ejemplares similares
-
Riociguat for pulmonary arterial hypertension associated with congenital heart disease
por: Rosenkranz, Stephan, et al.
Publicado: (2015) -
Right heart function during simulated altitude in patients with pulmonary arterial hypertension
por: Seccombe, Leigh M, et al.
Publicado: (2017) -
Prognostic impact of follow-up pulmonary vascular resistance in pulmonary arterial hypertension
por: Suzuki, Sho, et al.
Publicado: (2022) -
COVID-19 AS A PRIMARY CAUSE OF PULMONARY ARTERIAL HYPERTENSION
por: RAVAL, ABHIJIT, et al.
Publicado: (2021) -
Right ventricular remodelling in pulmonary arterial hypertension predicts treatment response
por: Goh, Ze Ming, et al.
Publicado: (2022)